Dental Erosion Clinical Trial
Official title:
Exploratory Evaluation of an Experimental Fluoride Dentifrice Formulation Using an in Situ Remineralization/Fluoride Uptake Model
Verified date | May 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether an experimental fluoridated dentifrice is effective in the treatment of dental caries
Status | Completed |
Enrollment | 20 |
Est. completion date | January 2008 |
Est. primary completion date | January 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 78 Years |
Eligibility |
Inclusion Criteria: 1. Age: Aged between 18 and 78 2. Fluoride: Currently living in the Indianapolis area which has a fluoridated water supply (1 ppm F) and not taking fluoride supplements for medical reasons 3. Dentures: Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 x 7 mm). Willing and capable of wearing their removable partial dentures 24 hours per day during the experimental periods 4. Dental health:Have no current active caries or periodontal disease that may compromise the study or the health of the participants and all restorations in a good state of repair 5. Salivary flow:Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate = 0.2 mL/min; gum base stimulated whole saliva flow rate = 0.8 mL/min 6. Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions 7. Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form 8. General Health: Good general health with (in the opinion of the investigator) no clinically significant and/or relevant abnormalities of medical history or oral examination that could interfere with participant safety during the study period Exclusion Criteria: 1. Antibiotics:Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit 2. Allergy/Intolerance:Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients 3. Pregnancy:Women who are known to be pregnant or who are intending to become pregnant over the duration of the study. 4. Breast-feeding:Women who are breast-feeding. 5. Clinical Study/Experimental Medication: Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit 6. Personnel:An employee of the sponsor or the study site who is directly involved in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage Surface Micro-hardness Recovery (SMHR) of Enamel Specimens | SMH test was used to assess mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents re-hardening of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline (B), after intra-oral exposure (R) and after in-vitro demineralization (D) using formula: [(D-R)/ (D-B)]*100. | Baseline to 14 days | |
Secondary | Adjusted Mean Change From Baseline in Enamel Fluoride Uptake | Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores and expressed as ug*F/cm^3. The difference between treatments was calculated with respect to fluoride uptake by enamel. | Baseline to 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04208802 -
Effect of Smoking on Saliva Composition and the Development of Dental Erosion
|
||
Not yet recruiting |
NCT04033263 -
Maintaining Oral Health With Bio-products
|
N/A | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT04095520 -
12 Months Clinical Follow-up of Non-Carious Cervical Lesions Restored With New Injectable Composite
|
N/A | |
Completed |
NCT03311438 -
Oral Health Intervention Program for Children With Congenital Heart Defects
|
N/A | |
Completed |
NCT04586322 -
Association Between Erosive Tooth Wear Progression and Dietary Risk Factors.
|
||
Completed |
NCT01657903 -
Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion
|
N/A | |
Enrolling by invitation |
NCT06156618 -
The Effect of Nitrate Supplement on the Oral Microbiome and Saliva in Dental Erosion
|
N/A | |
Suspended |
NCT02775149 -
Dental Erosion in Patients With Gastro-oesophageal Reflux
|
||
Active, not recruiting |
NCT05371717 -
Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite
|
N/A | |
Completed |
NCT02780973 -
Influence of Gender Specific Differences of Saliva Composition on the Development of Dental Erosion - an In-situ Study
|
||
Completed |
NCT03426150 -
Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks
|
Phase 4 | |
Not yet recruiting |
NCT06171594 -
The Effect of Chlorhexidine on the Oral Microbiome and Saliva in Dental Erosion
|
N/A | |
Completed |
NCT05140538 -
A New Protocol for the Management of Dental Erosion in Rugby Players
|
N/A | |
Recruiting |
NCT02087345 -
Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion
|
||
Not yet recruiting |
NCT04602572 -
Obesity and Oral Diseases in Adult Patients
|